Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.37 |
| ▸ | NOS1 | P29475 | 1/20 | 0.34 |
| ▸ | NOS2 | P35228 | 1/20 | 0.34 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.33 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.31 |
| ▸ | SRC | P12931 | 1/20 | 0.31 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL240584 | 0.85 | — | — | |
| Bromide SCHEMBL5516150 | 0.83 | — | — | |
| Hydrochloric Acid SCHEMBL2222 | 0.83 | — | — | |
| Trifluoroacetic Acid SCHEMBL2366949 | 0.83 | DGAT1 (0.34) | DGAT1NOS1NOS2KCNN4CTRB1 | |
| Trifluoroacetic Acid SCHEMBL2544145 | 0.81 | CNR2 (0.32) | DGAT1ALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL28075338 | 0.80 | KCNN4 (0.38) | DGAT1KCNN4CTRB1ALDH1A1TSHR | |
| Trifluoroacetic Acid SCHEMBL2267588 | 0.77 | ALDH1A1 (0.44) | NOS1NOS2ALDH1A1TSHR | |
| Trifluoroacetic Acid SCHEMBL2392878 | 0.75 | NOS1 (0.42) | NOS1NOS2ALDH1A1TSHR | |
| Trifluoroacetic Acid SCHEMBL27552120 | 0.75 | F2 (0.37) | NOS1NOS2ALDH1A1TSHR | |
| SCHEMBL30150871 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9227995-B2 | Peptides | Jacobsen, Øyvind (NO) | 2016-01-05 | — | — | US | disclosed |
| EP-2212334-B1 | PROTEASOME INHIBITORS | MILLENNIUM PHARM INC (US) | 2012-08-15 | — | — | EP | disclosed |
| US-20110263479-A1 | Peptides | UNIVERSITETET I OSLO (NO) | 2011-10-27 | — | — | US | disclosed |
| US-7838673-B2 | Proteasome inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-11-23 | — | — | US | disclosed |
| EP-2212334-A1 | PROTEASOME INHIBITORS | Millennium Pharmaceuticals, Inc. (US) | 2010-08-04 | — | — | EP | disclosed |
| WO-2009051581-A1 | PROTEASOME INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-04-23 | — | — | WO | disclosed |
| US-20090099132-A1 | Proteasome inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263479-A1 | Peptides | VIP, NGLY1, NPPA | DGAT1 4788/4885NOS1 3945/4885NOS2 3795/4885 |
| US-20090099132-A1 | Proteasome inhibitors | PSMB5, PSMG3, PSMB1 | DGAT1 3438/4885NOS1 4239/4885NOS2 4484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.